Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Nippon Venture Capital Co., Ltd. (NVCC) was founded on February 1, 1996, and is headquartered in Tokyo, Japan. The firm focuses on supporting entrepreneurs and venture companies poised to lead the next generation. NVCC collaborates with experienced business leaders and large corporations to provide multifaceted support to its portfolio companies.
NVCC invests in startup and early-stage companies across healthcare, digital health, energy, and biotech sectors. The firm participates in funding from pre-seed to Series A stages, emphasizing a neutral stance to contribute to Japan's venture ecosystem. Investments are supported by a network of over 200 large corporations that help evaluate business viability and foster alliances post-investment.
Notable portfolio companies include Hepalis Pharma Co., Ltd. (Medical), movus technologies Co., Ltd. (Services), RYDE Co., Ltd. (Information and Communication), MetaGene Therapeutics Co., Ltd. (Medical), and AudioStock Co., Ltd. (Information and Communication). Other investments span various sectors, including WHILL Co., Ltd. (Manufacturing) and Awarefy Co., Ltd. (Digital Health).
Submit your pitch through their form at https://nvcc.co.jp.
Yes, NVCC often leads funding rounds for its portfolio companies, particularly in the early stages of development.
NVCC is open to follow-on investments, supporting companies as they progress towards public listing.
The specific size of NVCC's current fund is not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.